Martin Helmut Stradner

Dr. Martin Helmut Stradner

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Gastroenterology
Verified
Journal Article
Closed access
KPKatrin Panzitt
Katrin Panzitt
MTMarisa M.O. Tschernatsch
Marisa M.O. Tschernatsch
CGChristian Guelly
Christian Guelly
TMTarek Moustafa
Tarek Moustafa
MSMartin Helmut Stradner
Martin Helmut Stradner
KZKurt Zatloukal
Kurt Zatloukal

29 September 2013 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ADAndrew L Doedens
Andrew L Doedens
APAnthony T Phan
Anthony T Phan
MSMartin Helmut Stradner
Martin Helmut Stradner
JFJessica K Fujimoto
Jessica K Fujimoto
JNJessica V Nguyen
Jessica V Nguyen
AGAnanda W Goldrath
Ananda W Goldrath

1 January 2014 in Cell Stem Cell
Verified
Journal Article
Closed access
ZRZhili Rong
Zhili Rong
MWMeiyan Wang
Meiyan Wang
ZHZheng Hu
Zheng Hu
MSMartin Helmut Stradner
Martin Helmut Stradner
SZShengyun Zhu
Shengyun Zhu
XFXuemei Fu
Xuemei Fu

14 January 2017 in Molecules
Verified
Journal Article
Open access
PDF file
PFPatrizia Fasching
Patrizia Fasching
MSMartin Helmut Stradner
Martin Helmut Stradner
WGWinfried B. Graninger
Winfried B. Graninger
CDChristian Dejaco
Christian Dejaco
JFJohannes Fessler
Johannes Fessler
A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was recently implicated in various autoimmune disorders. Tregs are responsible for the maintenance of self-tolerance, thus inhibiting autoimmunity, whereas pro-inflammatory Th17-cells contribute to the induction and propagation of inflammation. Distortion of the Th17/Treg balance favoring the pro-inflammatory Th17 side is hence suspected to contribute to exacerbation of autoimmune disorders. This review aims to summarize recent data and advances in targeted therapeutic modification of the Th17/Treg-balance, as well as information on the efficacy of candidate therapeutics with respect to the treatment of autoimmune diseases.

1 December 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
CDChristian Dejaco
Christian Dejaco
MSMartin Helmut Stradner
Martin Helmut Stradner
DZDorothea Zauner
Dorothea Zauner
WSWerner Seel
Werner Seel
NSNicole Elisabeth Simmet
Nicole Elisabeth Simmet
SQStefan Quasthoff
Stefan Quasthoff
To compare ultrasound measurement of median nerve cross-sectional area (CSA) at different anatomical landmarks and to assess the value of power Doppler signals within the median nerve for diagnosis of carpal tunnel syndrome (CTS). A prospective study of 135 consecutive patients with suspected CTS undergoing two visits within 3 months. A final diagnosis of CTS was established by clinical and electrophysiological findings. CSA was sonographically measured at five different levels at forearm and wrist; and CSA wrist to forearm ratios or differences were calculated. Intraneural power Doppler signals were semiquantitatively graded. Diagnostic values of different ultrasound methods were compared by receiver operating characteristic curves using SPSS. CTS was diagnosed in 111 (45.5%) wrists; 84 (34.4%) had no CTS and 49 (20.1%) were possible CTS cases. Diagnostic values were comparable for all sonographic methods to determine median nerve swelling, with area under the curves ranging from 0.75 to 0.85. Thresholds of 9.8 and 13.8 mm(2) for the largest CSA of the median nerve yielded a sensitivity of 92% and a specificity of 92%. A power Doppler score of 2 or greater had a specificity of 90% for the diagnosis of CTS. Sonographic median nerve volumetry revealed a good reliability with an intraclass correlation coefficient of 0.90 (95% CI 0.79 to 0.95). Sonographic assessment of median nerve swelling and vascularity allows for a reliable diagnosis of CTS. Determination of CSA at its maximal shape offers an easily reproducible tool for CTS classification in daily clinical practice.

1 February 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JFJohannes Fessler
Johannes Fessler
RHRusmir Husic
Rusmir Husic
VSVerena Schwetz
Verena Schwetz
ELElisabeth Lerchbaum
Elisabeth Lerchbaum
FAFelix Aberer
Felix Aberer
CDChristian Dejaco
Christian Dejaco
Objective: T-cells are critical players in the pathogenesis of osteoporosis in patients with rheumatoid arthritis (RA). Premature senescence of lymphocytes including the accumulation of senescent CD4+ T-cells is a hallmark feature of RA. Whether T-cell senescence is associated with bone loss in RA patients is elusive so far. Methods: This includes a prospective study of consecutive patients with RA (n = 107), patients with primary osteopenia/-porosis (n = 75), and healthy individuals (n = 38). Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometry scan. Flow cytometry, magnetic-associated cell sorting, and cell culture experiments were performed to analyze the pro-osteoclastic phenotype and the function of senescent CD4+CD28− T-cells. Results: Patients with osteopenia/-porosis yielded a higher prevalence of senescent CD4+CD28− T-cells than individuals with normal BMD, in the RA, as well as in the non-RA cohort. Receptor activator of nuclear factor kappa-B ligand (RANKL) was expressed at higher levels on CD4+CD28− T-cells as compared to CD28+ T-cells. Stimulation with interleukin-15 led to an up-regulation of RANKL expression, particularly on CD28− T-cells. CD4+CD28− T-cells induced osteoclastogenesis more efficiently than CD28+ T-cells. Conclusion: Our data indicate that senescent T-cells promote osteoclastogenesis more efficiently than conventional CD28+ T-cells, which might contribute to the pathogenesis of systemic bone loss in RA and primary osteoporosis.